FDA extends Evkeeza approval to treat children as young as 1 with HoFH

Regeneron (REGN) secured FDA approval for Evkeeza to treat homozygous familial hypercholesterolemia (HoFH) in children aged 1 to under 5 years, expanding the drug's market for this rare genetic condition and highlighting its growth in specialized treatments. This development, which follows clinical data showing significant LDL-C reduction, comes as the company also reported positive Phase 3 results for garetosmab in FOP, enhanced survival with Libtayo in lung cancer, and successful allergy treatments, underscoring its robust pipeline. InvestingPro analysis indicates Regeneron maintains "GREAT" financial health and may be trading below its Fair Value.

Analysis

Regeneron Pharmaceuticals (NASDAQ:REGN) has secured a significant label expansion with the FDA's approval of Evkeeza for children aged 1 to 5 with homozygous familial hypercholesterolemia (HoFH), a rare genetic condition affecting approximately 1,300 people in the U.S. This approval, which received Priority Review, follows prior expansions for older age groups and is supported by data showing the drug reduces LDL-C by approximately 50% when added to standard therapies. This regulatory win is compounded by a series of positive clinical trial results that underscore the depth of the company's pipeline. Notably, its Phase 3 trial for garetosmab in FOP met its primary endpoint with a greater than 90% reduction in new bone lesions, while its immunotherapy drug Libtayo demonstrated a 19.4% five-year overall survival rate in advanced lung cancer, doubling the rate of chemotherapy alone. Furthermore, successful Phase 3 trials for cat and birch allergy treatments highlight progress in another therapeutic area. These developments are supported by strong underlying fundamentals, as indicated by an InvestingPro "GREAT" financial health score of 3.06 for the $57.6 billion market-cap company, with analysis suggesting its stock may be trading below fair value.

Key Decisions for Investors

• The consistent flow of positive regulatory and clinical news, spanning from the Evkeeza label expansion to multiple successful Phase 3 trial readouts, reinforces the company's strong R&D execution and provides tangible catalysts that support a bullish outlook.
• Given the company's robust financial health score of 3.06 and external analysis suggesting it is trading below fair value, investors should consider if the current valuation presents an attractive entry point, especially with several late-stage assets now significantly de-risked.
• Investors should monitor the commercial uptake of the newly approved Evkeeza indication and watch for forthcoming regulatory filings for garetosmab and the allergy treatments, as these represent key future revenue drivers beyond the company's established portfolio.